Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Adcetris (brentuximab vedotin ADC by Year
Adcetris (brentuximab vedotin ADC — lymphoma, via Seagen) — Worldwide reported YoY (%) (%)
Pfizer Adcetris (brentuximab vedotin ADC: -17.0% in FY2025.
Latest, FY2025
-17.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03)
Where the FY2025 figure comes from
“|| Adcetris (h) | 907 | 1,089 | (17%) | (17%) | 885 | 1,059 | (16%) | 23 | 30 | (25%) | (23%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Adcetris (brentuximab vedotin ADC — lymphoma, via Seagen) — Worldwide reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -17.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
Cite this data
StockData. (2026). Pfizer Adcetris (brentuximab vedotin ADC (%), annual FY2025–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/adcetris-yoy-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.